Elrexfio (elranatamab-bcmm) / Pfizer - LARVOL DELTA

Phase II Trial of Fixed-Duration Consolidation With Elranatamab Post-Idecabtagene Vicleucel CAR-T (EPIC) to Deepen Responses and MRD-Negativity in Relapsed or Refractory Multiple Myeloma (IMS 2026) - P2 | "Fixed-duration consolidation after ide-cel with Elra led to deepening of disease responses and MRD-conversion with ongoing, durable responses observed. The EPIC trial is fully accrued and updated data will be presented."

CAR T-Cell Therapy • Minimal residual disease • P2 data • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Plasmacytoma • Thrombocytopenia

Phase I/II Study of Mezigdomide and Elranatamab for Relapsed/Refractory Multiple Myeloma Patients (MELT-MM): Updated Results From Part 1 (IMS 2026) - P1/2 | "Eligible patients had R/R MM after ≥2 prior lines including a proteasome inhibitor and lenalidomide, were anti-BCMA–naïve, ECOG PS ≤2, with measurable disease. Mezigdomide plus elranatamab demonstrates profound and rapid antimyeloma activity with a manageable safety profile. Both 0.3 mg and 0.6 mg were selected as RP2Ds. Part 2 will proceed as a 1:1 randomized expansion (Arm A 0.3 mg vs."

Clinical • P1/2 data • Acute Kidney Injury • Cytomegalovirus Infection • Febrile Neutropenia • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Nephrology • Neutropenia • Renal Disease • Thrombocytopenia • IKZF1 • PD-1 • TIGIT

Elranatamab-bcmm (Elrexfio) plus mezigdomide produced preliminary response signals in patients with relapsed/refractory multiple myeloma, according to results from the phase 1b portion of the MELT-MM trial (NCT06645678) presented at the 23rd Annual International Myeloma Society (IMS) Meeting & Exposition. (Cancer Network) - "At a data cutoff of July 31, 2026, and a median follow-up of 13.7 months (range, 8.6-19.3) from cycle 0, day 1, all 13 evaluable patients achieved a response for an overall response rate (ORR) of 100%, including a stringent complete response (sCR) in 12 patients (92.3%) and a very good partial response in 1 patient (7.7%). The median time to response was 17 days (range, 11-45), and the median time to best response was 5.6 months (range, 3.3-5.9). Responses were consistent across the mezigdomide 0.3-mg (n = 7) and 0.6-mg (n = 6) dose cohorts and across subgroups, including patients with prior T-cell engager exposure, triple-class–refractory disease, penta-refractory disease, and soft tissue extramedullary disease, all of which had a 100% ORR....Patient-sample analyses supported the biological rationale for the combination."

P1 data • Multiple Myeloma

Carfilzomib, Iberdomide, and Dexamethasone (KID) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Results from a Phase 1/2 Study (IMS 2026) - P1/2 | "Introduction: Standard upfront regimens demonstrate stringent complete response (sCR) rates of 10-15% following induction, and 40% following consolidation in patients (pts) with newly diagnosed multiple myeloma (NDMM). Induction tx with KID achieved 31% sCR/CR rates post ASCT overall and 31% in the high-risk NDMM pts at interim analysis, despite short tx duration. All pts were successfully mobilized. Further studies will evaluate KID with post-ASCT iber + elranatamab consolidation followed by iber maintenance."

Clinical • P1/2 data • Atrial Fibrillation • Cardiovascular • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Targeted Protein Degradation • Thrombocytopenia • Transplantation • CRBN

Trial in Progress: Phase 1 Trial of Arlocabtagene Autoleucel (Arlo-Cel) Plus Mezigdomide (MEZI) or Elranatamab (ELRA) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) (IMS 2026) - P1 | "This trial will evaluate arlo-cel combinations, including with MEZI and ELRA maintenance, in RRMM."

Clinical • P1 data • Bone Marrow Transplantation • Hematological Malignancies • Multiple Myeloma • IKZF1

Treatment Outcomes in Primary Plasma Cell Leukaemia: A Single-Centre Experience of Novel Therapeutic Modalities Including Haploidentical Transplantation and Bispecific Antibody Therapy (IMS 2026) - "Despite advances including daratumumab-based induction regimens, outcomes remain dismal...High-dose melphalan (MEL200) auto-SCT was performed in 80% of patients, including one tandem auto-auto SCT... These findings suggest that the incorporation of novel treatment modalities may improve outcomes in pPCL. Allo-SCT appeared to confer durable benefit even following post-transplant relapse, consistent with ongoing graft-versus-myeloma immune surveillance. Haploidentical transplantation expands donor availability for patients from ethnic minority backgrounds — particularly Black patients, who face a disproportionately elevated risk of pPCL."

Bispecific • Clinical • Cerebral Hemorrhage • CNS Disorders • Hematological Malignancies • Leukemia • Multiple Myeloma • Transplantation

TARGET-LATAM Targeted Bispecific Antibodies Against BCMA and GPRC5D in Relapsed/Refractory Multiple Myeloma a Real-World Comparative Analysis from the GELAMM Group (IMS 2026) - "In this Latin American cohort of heavily pretreated RRMM patients, anti-BCMA (teclistamab/elranatamab) and anti-GPRC5D (talquetamab) bispecific antibodies demonstrated comparable efficacy in PFS and OS after propensity score matching. However, anti-BCMA therapy was associated with significantly higher rates of any-grade infectious toxicity (p < 0.001) and hypogammaglobulinemia < 400 mg/dL (p = 0.013), underscoring the importance of close infectious-disease monitoring and immunoglobulin replacement strategies in this population."

Bispecific • Clinical • Real-world • Real-world evidence • Hematological Malignancies • Infectious Disease • Multiple Myeloma

Systematic Review and Meta-Analysis of Tocilizumab Prophylaxis for Cytokine Release Syndrome (CRS) in Bispecific Antibody Therapy for Multiple Myeloma (IMS 2026) - "Databases (PubMed, Cochrane, Embase, Google Scholar) and ClinicalTrials.gov were searched with MeSH terms and keywords for tocilizumab, prophylaxis, CRS, bispecific, teclistamab, talquetamab, elranatamab, linvoseltamab, cevostamab, and multiple myeloma. A single prophylactic dose of tocilizumab before the first step-up dose consistently and substantially reduces CRS — to a pooled 9% with almost absence of grade ≥3 events. This low rate of CRS with prophylactic tocilizumab could lend to safe adoption of bispecifics in academic and community practices."

Bispecific • Cytokine release syndrome • Retrospective data • Review • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia

Shifting Landscapes in Triple-Class Exposed Multiple Myeloma in Latin America (LATAM): Real-World Outcomes with Bispecific Antibodies Versus Standard of Care (IMS 2026) - "Pts receiving BsAbs (teclistamab, talquetamab, or elranatamab) were compared with those treated with standard-of-care (SoC)-based salvage regimens. Belantamab mafodotin-treated pts were excluded from the primary comparative analysis due to limited sample size and retained for descriptive purposes only. SoC regimens were grouped as carfilzomib-based, pomalidomide-based, carfilzomib plus pomalidomide-based, chemotherapy-based, and other regimens... In this large real-world LATAM cohort of TCE-RRMM pts, BsAbs were associated with significantly improved response rates and survival outcomes compared with SoC, despite a population enriched with higher refractory burden and EMD prevalence. These findings support the effectiveness of BsAbs in routine clinical practice across LATAM and reinforce the importance of expanding access to novel immunotherapeutic strategies in the region."

Bispecific • Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma

Safety Profile and Impact of Body Weight on Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma (IMS 2026) - "Management included dexamethasone (n=5), tocilizumab (n=2), or both (n=6). While the incidences of CRS and infections were BW-independent, the higher incidence of rash in patients with lower BW suggests that this subgroup requires careful monitoring for dermatologic toxicity. Notably, the co-occurrence of transaminase elevation and rash with CRS reflects a manageable systemic inflammatory response rather than isolated organ toxicity. Furthermore, given the high baseline CMV seroprevalence in Japan, caution is warranted regarding the risk of CMV reactivation during ELRA treatment."

Clinical • Cytomegalovirus Infection • Hematological Malignancies • Immunology • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia • Plasmacytoma • Systemic Inflammatory Response Syndrome • Thrombocytopenia

Safety and Feasibility of Outpatient Bispecific Antibodies Step-Up Doses Administration for the Treatment of Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Study. (IMS 2026) - " Overall, 86 patients (pts) received outpt bsAb SUD (30 teclistamab, 16 elranatamab, 40 talquetamab) in 18 Italian centers (ctr), with a median follow up of 7 (range 1-35) months (m)...Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome prevention strategies (CRS/ICANS-PS) consisted in per label premedication for all pts; in addition, 26 (30%) received prophylactic tocilizumab (PT), 33 (38%) dexamethasone post medication and 6 (7%) both... Our RW results support outpt bsAb SUD as a safe and viable option with the use of structured protocols, with PT emerging as the most effective strategy to reduce CRS and facilitate SUD completion in this setting."

Bispecific • Clinical • Real-world • Real-world evidence • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma

Real-World Patient Characteristics, General Safety Profile, and Treatment Patterns of Elranatamab (ELRA) Use in Relapsed Refractory Multiple Myeloma (RRMM): Interim Results of the Ambrela Study (IMS 2026) - P2 | "Overall, pts in AMbrELA were older with a poorer general condition than BCMA- naive pts in MM-3. The RW ELRA safety profile was consistent with that in MM-3, except for lower CRS and infection rates, which may reflect improved management in routine clinical practice in France. ELRA dosing appeared to transition to Q4W more rapidly than recommended."

Clinical • Real-world • Real-world evidence • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia

Real-World Effectiveness of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma in Japan: Results from the SUMMIT Study (IMS 2026) - "These results suggest that ELRA demonstrates clinically meaningful effectiveness in RW practice among Japanese patients with RRMM, with outcomes generally consistent with the clinical trial results. As median rwOS and rwTTNT were not reached, longer follow-up will be needed to fully characterize RW effectiveness."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Hematological Malignancies • Multiple Myeloma • Renal Disease

Real-World Burden of Infections in Patients with Relapsed or Refractory Multiple Myeloma Treated with Elranatamab in Japan: Findings from the SUMMIT Study (IMS 2026) - "In this real-world RRMM cohort receiving ELRA in Japan, infection diagnoses were observed in approximately half of patients during follow-up, with bacterial infections being the most common. These findings highlight the need for infection awareness and close monitoring in clinical practice."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Infectious Disease • Multiple Myeloma

Real-World (RW) Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) in Europe: Results from the HARMONY Big Data Platform (IMS 2026) - "Overall, 92% (n=458) were exposed to daratumumab, with 87% first receiving it in 2L and 5% in 1L...In the 3L cohort (n=152), >40 unique regimens were used; top regimens were carfilzomib-dexamethasone (dex) (16%), pomalidomide-dex (14%), and bortezomib-pomalidomide-dex (11%). Across the 2020+ subgroup (N=415), utilization of BsAbs in index LoT was low: teclistamab (18 [4%]), talquetamab (8 [2%]), elranatamab (2 [ < 1%])... European RW data, primarily from the Czech Republic, show fragmented treatment patterns for 3L+ TCE RRMM. Pts relapse quickly and survival worsens with later LoT. Despite the approval of novel immunotherapies, RW uptake remains limited and outcomes continue to be poor, highlighting the need for more effective and broadly accessible therapies."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma

Prior BCMA Exposure in Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab or Elranatamab from the IMWG Immunotherapy Registry (IMS 2026) - "Outcomes for patients receiving tec/ elra after prior BCMA were poor, particularly following BCMA bsAb. However, benefits were seen in prior ADC and CART cohorts, particularly with a ≥ 9-month interval between BCMA treatments. Additional data including safety after prior BCMA exposure will be presented at the meeting."

Clinical • Hematological Malignancies • Multiple Myeloma

Preemptive Tocilizumab in Patients with Relapsed-Refractory Multiple Myeloma Receiving Bispecific: A Case Series (IMS 2026) - "Teclistamab (Tec), talquetamab (Tal), and elranatamab (Elra) are bispecific antibodies (BsAbs) approved for relapsed-refractory multiple myeloma (RRMM)...All patients received intravenous immunoglobulin to maintain functional IgG ≥500 mg/dL, filgrastim to maintain absolute neutrophil 1.00 K/mcL, epoetin alfa to maintain hemoglobin above 10 g/dL, and romiplostim to maintain platelets above 50 K/mcL...The only incident of CRS occurred with a single patient who developed grade 1 CRS on C1D3 which resolved after one dose of dexamethasone 10 mg... Preemptive Toci may decrease the incidence and severity of CRS in patients with RRMM receiving BsAbs, without compromising response. In this small observational analysis, no patients experienced prolonged hospitalization for management of CRS."

Bispecific • Clinical • Hematological Malignancies • Infectious Disease • Multiple Myeloma

Outpatient Administration of Bispecific Antibody Therapy for Multiple Myeloma in Community Oncology Practice (IMS 2026) - "Eligibility required continuous caregiver availability, residence within 60 miles of a designated site with tocilizumab access, and absence of significant comorbidities... Seven RRMM patients underwent outpatient SUD (teclistamab n=3, talquetamab n=3, elranatamab n=1) from March 2025 to February 2026... This experience demonstrates the feasibility of fully outpatient BsAb SUD in a community oncology setting. Most adverse events were manageable at home or in the outpatient setting. Multidisciplinary protocols, caregiver education, and defined eligibility criteria were central to safe implementation."

Bispecific • Clinical • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Pneumonia • Respiratory Diseases

Interim Report of Phase I Results of a Phase I/II, Open Label Study to Evaluate Safety, Tolerability, and Efficacy of Elranatamab in Patients With Relapsed AL Amyloidosis (IMS 2026) - " Adult patients with AL amyloidosis who had progressed or were refractory to at least 1 prior line of therapy, inclusive of daratumumab and/or cyclophosphamide/bortezomib/dexamethasone were eligible...Tocilizumab was used in 3 patients, additional steroids used in 2 patients, and supplemental oxygen in 2 patients (37.5%)... Elranatamab demonstrated no new safety signals and rapid, deep and frequent hematological response in patients with relapsed, AL amyloidosis, representing a promising therapeutic option to address this critical unmet need."

Clinical • P1/2 data • Amyloidosis • Hematological Malignancies • Multiple Myeloma

Low CRS and ICANS Rates During Step Up Dose Reinitiation After Prolonged Dose Delay of Bispecific Antibodies in Multiple Myeloma (IMS 2026) - " Between Jan 2020 and May 2026, 221 patients received teclistamab, elranatamab or talquetamab...Dexamethasone was given as premedication and all CRS events were treated successfully with 1 dose of tocilizumab... CRS and ICANS rates were low during reSUD following prolonged dose delay of bispecific antibodies, particularly among patients in VGPR or CR who were well established in treatment. For these patients, reSUD may be safely administered in outpatient settings, avoiding costly inpatient stays. More studies are needed to ascertain the optimal SUD levels after dose delays and ways to mitigate CRS and ICANS risks in these situations."

Bispecific • Acute Kidney Injury • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Nephrology • Novel Coronavirus Disease • Renal Disease

Integrated Single-Cell and Proteomic Profiling Reveal Immune Mechanisms of Response and Resistance to BCMAxCD3 Bispecific Antibodies in the RESISTEC Study. (IMS 2026) - " We performed a longitudinal immunogenomic analysis of RRMM patients from the IFM RESISTEC study treated with BCMA×CD3 bispecific antibodies (teclistamab or elranatamab). Response to BCMA×CD3 bispecific antibodies is associated with dynamic clonal remodeling characterized by expansion of BM-derived interferon-primed CD8 ⁺ T-cell clones that differentiate into circulating cytotoxic effectors. In contrast, non-responders exhibit activation of suppressive Treg programs and proteomic signatures associated with tumor burden. These findings identify coordinated immune, clonal, and proteomic mechanisms underlying response and resistance to BsAbs and provide a rationale for predictive biomarkers and novel combinatorial therapeutic strategies in RRMM."

Bispecific • IO biomarker • Hematological Malignancies • Multiple Myeloma • CD4 • CD8 • FOXP3

Impact of Prior Anti-Bcma Antibody-Drug Conjugate Exposure and High-Risk Cytogenetics on Outcomes with BCMA Bispecifics in Relapsed/Refractory Multiple Myeloma: A Single Centre Real-World Analysis (IMS 2026) - "Median PFS was 9.8 months, with no difference between teclistamab and elranatamab (HR 1.05, p=0.87). Fourteen patients (25%) had prior belantamab mafodotin exposure and all were ADC-refractory before TCE treatment...Prior belantamab exposure did not adversely affect PFS following TCE therapy (HR 1.29, 95%CI 0.61–2.69; p=0.5); 12-month PFS was 48% versus 53% in belantamab-exposed versus non-exposed patients, respectively... In this real-world RRMM cohort with prolonged follow-up, prior anti-BCMA ADC exposure did not impair outcomes of subsequent BCMA-targeting TCE therapy. Conversely, extramedullary disease and cumulative HRCA burden remained associated with inferior outcomes, supporting their continued prognostic relevance in the bispecific antibody era."

ADC • Bispecific • Clinical • Real-world • Real-world evidence • Hematological Malignancies • Multiple Myeloma • Plasmacytoma

Impact of Infusion Timing in Multiple Myeloma Patients Receiving Bispecific Antibody Therapy: A Single-Institution Retrospective Analysis (IMS 2026) - "Agents included teclistamab (52.4%), talquetamab (23.8%), elranatamab (19.0%), and teclistamab/talquetamab (4.8%). In this single-institution retrospective analysis, morning BsAb administration was associated with significantly lower CRS incidence than afternoon dosing (25.0% vs 70.6%, OR 0.14, p=0.038) without compromising response rates or time to response. Consistent odds ratios across the full and first-course analyses (OR 0.14 vs 0.17) suggest the loss of significance in the sensitivity analysis reflects reduced power rather than a diminished effect. These hypothesis-generating findings suggest infusion timing may represent a modifiable strategy to mitigate CRS risk, warranting further investigation ."

Bispecific • Retrospective data • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma

Fixed-Duration Versus Continuous Bispecific Antibody Therapy Regimen for Systemic AL Amyloidosis (IMS 2026) - "About 50% of patients do not achieve hematologic complete response (hCR) with daratumumab-based therapy, and many relapse. ASCT is restricted to select patients; immunomodulators have renal/cardiac toxicity, and venetoclax benefits t(11;14) cases...11 patients received Elranatamab vs 9 Teclistamab vs 1 Talquetamab... Fixed-duration BSAb therapy led to rapid, deep hematologic responses comparable to continuous therapy, despite higher baseline risk. Organ responses were seen in both groups, with similar response durability. Fixed-duration therapy had fewer neutropenia and infection events."

Bispecific • Amyloidosis • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Neutropenia

Eosinophilia Associated with Elranatamab in Patients with Multiple Myeloma: A Multi-Institutional Analysis (IMS 2026) - " We retrospectively evaluated multiple myeloma patients treated with elranatamab (elra; n=181), teclistamab (tec; n=138), and linvoseltamab (linvo; n=44) as monotherapy across three academic centers (n=363)... Prophylactic medications, including sulfamethoxazole/trimethoprim, were standard across institutions and BCMA TCE products... Elra demonstrated a distinct eosinophilic toxicity profile among BCMA-TCE, characterized by higher incidence, greater severity, and infrequent but severe systemic inflammatory manifestations often independent of rash and generally not meeting criteria for DRESS. While the mechanism is unknown, recognition of this syndrome is clinically important. Continued elra dosing with corticosteroids in asymptomatic and/or low-grade cases appears feasible and effective."

Clinical • Eosinophilia • Gastrointestinal Disorder • Hematological Malignancies • Multiple Myeloma • Myeloproliferative Neoplasm